MERCK REPORTS JANUVIA DATA

A A

Merck has announced that Januvia, its oral, once-daily medicine for Type 2 diabetes, significantly reduced blood sugar levels when used alone or as an add-on treatment to two commonly used therapies (metformin or pioglitazone) in a Phase III trial.

Treatment with Januvia also improved measures of beta cell function, said the company. Beta cells are cells in the pancreas that make and release insulin.

In the studies, Januvia had an overall incidence of side effects comparable to placebo and was generally well-tolerated.